Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Experimental Neurology

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.EXPNEUROL.2003.08.007PMID 14637123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.

  2003influential reference
• Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

  2002cited by this paper
• Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, neonatal and adult brains.

  2002cited by this paper
• Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

  2002cited by this paper
• Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats.

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration

  2002influential reference
• CMV-β-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1α Promoter and Results in Therapeutic Levels of Human Factor X in Mice

  2001cited by this paper
• Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration

  2001cited by this paper
• Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.

  2001cited by this paper
• Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain.

  2001cited by this paper
• Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

  2001cited by this paper
• Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

  2001cited by this paper
• Sustained delivery of GDNF: towards a treatment for Parkinson's disease.

  2001cited by this paper
• Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system.

  2000cited by this paper
• Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• THE DEVELOPMENT OF HUMAN GENE THERAPY

  1999cited by this paper
• Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

  1999cited by this paper
• Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.

  1999influential reference
• Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivo

  1998cited by this paper
• Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.

  1998cited by this paper
• The primate nervous system

  1997cited by this paper
• From transplants to gene therapy for Parkinson's disease.

  1997cited by this paper
• Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.

  1997cited by this paper
• Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery

  1997cited by this paper
• Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

  1997cited by this paper
• GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis

  1997cited by this paper
• Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap

  1997cited by this paper
• PET studies of functional compensation in a primate model of Parkinson's disease

  1997cited by this paper
• Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system

  1996cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper
• GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

  1995cited by this paper
• Adeno-associated Viral Vectors

  1995cited by this paper
• The cryptic life style of adenoassociated virus

  1995cited by this paper
• Behavioural analysis of unilateral monoamine depletion in the marmoset.

  1992cited by this paper
• Use of adeno-associated virus as a general transduction vector for mammalian cells.

  1992cited by this paper
• Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

  1991cited by this paper
• The efficiency of systematic sampling in stereology and its prediction *

  1987cited by this paper
• Book reviewHandbook of Chemical Neuroanatomy: Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series).

  1986cited by this paper
• Localization of nigrostriatal, nigrothalamic and nigrotectal neurons in ventricular coordinates in macaques.

  1984cited by this paper
• The Brain of the Common Marmoset (Callithrix jacchus). A Stereotaxic Atlas, 91, H. Stephan, G. Baron, W.K. Schwerdtfeger. Springer-Verlag, Berlin-Heidelberg-New York (1980), pages, 5 figures, 3 tables, 73 plates, Price: Cloth 168 DM; approx. 94,10 US $

  1982cited by this paper

• Treatment of Parkinson’s Disease with Traditional Chinese Medicine and Western Medicine

  2026cites this paper
• Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases

  2024cites this paper
• Unraveling the role of glial cell line–derived neurotrophic factor in the treatment of Parkinson’s disease

  2023cites this paper
• Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies

  2022cites this paper
• Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.

  2022cites this paper
• Trophic factors for Parkinson's disease: Where are we and where do we go from here?

  2019cites this paper
• Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease

  2019cites this paper
• Pathology, Prevention and Therapeutics of Neurodegenerative Disease

  2019cites this paper
• Non-human primate models of PD to test novel therapies

  2018cites this paper
• Gene Therapy for Parkinson’s Disease, An Update

  2018cites this paper
• Therapeutic Application of Stem Cell and Gene Therapy in Parkinson’s Disease

  2018cites this paper
• Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo

  2017cites this paper
• Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms

  2017cites this paper
• Role of Neurotrophic Factors in Parkinson's Disease.

  2017cites this paper
• Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.

  2017cites this paper
• Current Experimental Studies of Gene Therapy in Parkinson's Disease

  2017cites this paper
• A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses

  2016cites this paper
• Adeno-Associated Virus-Based Gene Therapy for CNS Diseases

  2016cites this paper
• Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease

  2016cites this paper
• Promising therapeutic agents for the treatment of Parkinson’s disease

  2016cites this paper
• Expert Opinion on Biological Therapy

  2016cites this paper
• Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease

  2015cites this paper
• Translational research for Parkinson׳s disease: The value of pre-clinical primate models.

  2015cites this paper
• Viral vector delivery of neurotrophic factors for Parkinson's disease therapy

  2015cites this paper
• Transgenic expression of human glial cell line-derived neurotrophic factor ( hGDNF ) from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson ' s disease

  2015cites this paper
• Advances in non-dopaminergic treatments for Parkinson's disease

  2014cites this paper
• Transgenic Expression of Human Glial Cell Line-Derived Neurotrophic Factor from Integration-Deficient Lentiviral Vectors is Neuroprotective in a Rodent Model of Parkinson's Disease

  2014cites this paper
• Intranasal Delivery of pGDNF Nanoparticles for Parkinson's Disease

  2013cites this paper
• Trophic Factor Gene Therapy for Parkinson's Disease

  2013cites this paper
• Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

  2013cites this paper
• Gene-based Therapies in Parkinson’s Disease

  2013cites this paper
• A next step in adeno‐associated virus‐mediated gene therapy for neurological diseases: regulation and targeting

  2013cites this paper
• PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson’s Disease

  2012cites this paper
• Adeno-Associated Virus Type 2 Vector-Mediated Glial Cell Line-Derived Neurotrophic Factor Gene Transfer Induces Neuroprotection and Neuroregeneration in a Ubiquitin-Proteasome System Impairment Animal Model of Parkinson’s Disease

  2012cites this paper
• Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

  2012cites this paper
• Gene-based therapy of Parkinson’s Disease: Translation from animal model to human clinical trial employing convection enhanced delivery

  2012cites this paper
• Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.

  2012cites this paper
• Cellular Therapies for Huntington’s Disease

  2012cites this paper
• Behavioural analysis of 6-hydroxydopamine rodent models of Parkinson's disease

  2012cites this paper
• GDNF family ligands: a potential future for Parkinson's disease therapy.

  2011cites this paper
• Cell transplantation and gene therapy in Parkinson's disease.

  2011cites this paper
• Repairing the parkinsonian brain with neurotrophic factors.

  2011cites this paper
• Actions of GDNF on Midbrain Dopaminergic Neurons: The Signaling Pathway

  2011cites this paper
• Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity

  2010cites this paper
• Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF

  2010cites this paper
• Widespread cortical expression of MANF by AAV serotype 7: localization and protection against ischemic brain injury.

  2010cites this paper
• Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

  2010cites this paper
• Gene therapy for Parkinson's disease

  2010cites this paper
• Neurotrophic factor therapy for Parkinson's disease.

  2010cites this paper
• Rotation, Drug-induced

  2010cites this paper
• GDNF--a potential target to treat addiction.

  2009cites this paper
• Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model

  2009cites this paper
• Are growth factors the answer?

  2009cites this paper
• Large animal models of neurological disorders for gene therapy.

  2009cites this paper
• Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease.

  2009cites this paper
• Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

  2009cites this paper
• Architectural subdivisions of medial and orbital frontal cortices in the marmoset monkey (Callithrix jacchus)

  2009cites this paper
• Trophic factors therapy in Parkinson's disease.

  2009cites this paper
• Potential cellular and regenerative approaches for the treatment of Parkinson’s disease

  2008cites this paper
• Intranasal delivery of GDNF for the treatment of Parkinson's Disease

  2008cites this paper
• Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys

  2008cites this paper
• Preclinical development of gene therapy for Parkinson's disease.

  2008cites this paper
• The need for regulatable vectors for gene therapy for Parkinson's disease.

  2008cites this paper
• Animal Models of Parkinson’s Disease

  2008cites this paper
• 34 Animal Models of Parkinson's Disease

  2008cites this paper
• Contributions of non-human primates to neuroscience research.

  2008cites this paper
• Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.

  2008cites this paper
• Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

  2007cites this paper
• Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

  2007cites this paper
• Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.

  2007cites this paper
• Prospects of treating neurological diseases by gene therapy.

  2007cites this paper
• Gene transfer therapy for neurodegenerative disorders

  2007cites this paper
• The role of stem cells in Parkinson's disease.

  2007cites this paper
• Prospects for gene therapy in inherited neurodegenerative diseases

  2007cites this paper
• [Gene therapy for Parkinson's disease].

  2007cites this paper
• Gene therapy approaches for the treatment of Parkinson's disease.

  2007cites this paper
• Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector.

  2007cites this paper
• Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.

  2006cites this paper
• Cell-Based Therapy for Huntington’s Disease

  2006cites this paper
• Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease

  2006cites this paper
• Optic nerve regeneration in adult rat

  2006cites this paper
• Recombinant Adeno-Associated Viral Vectors for CNS Gene Therapy

  2006cites this paper
• CHAPTER 9 – Nonhuman Primate Models for Testing Gene Therapy for Neurodegenerative Disorders

  2006cites this paper
• Development of Viral Tools for CNS Gene Transfer: Adeno-Associated Viral Vectors in Gene Therapy of Parkinson's Disease

  2006cites this paper
• CHAPTER 8 – Gene Therapy for Parkinson's Disease

  2006cites this paper
• Lentiviral vectors for use in the central nervous system.

  2006cites this paper
• Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models

  2006cites this paper
• Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.

  2006cites this paper
• Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease

  2005cites this paper
• Recombinant Adeno-Associated Viral Vectors in the Nervous System

  2005cites this paper
• AAV for disorders of the CNS

  2005cites this paper
• Adeno-associated virus (AAV) vectors in the CNS.

  2005cites this paper
• Assessment of GDNF in Primate Models of Parkinson's Disease: Comparison with Human Studies

  2005cites this paper
• Marmoset monkey models of Parkinson's disease: which model, when and why?

  2005cites this paper
• Adeno-Associated Virus (AAV) Vectors in the CNS.

  2005cites this paper
• GDNF and Addiction

  2005cites this paper
• Adeno‐associated viral vectors for gene therapy

  2005cites this paper
• Dementia in Parkinson’s disease – causes and treatment Review: Dementia in Parkinson’s disease: cause and treatment (pp 399–404)

  2004cites this paper
• Article Commentary: A Perspective on Transplantation Therapy and Stem Cells for Parkinson's Disease1

  2004cites this paper
• Evaluation of animal models of Parkinson's disease for neuroprotective strategies.

  2004cites this paper